|
|
|
|
|
13.02.26 - 13:33
|
Corporate News: KPS AG (EQS)
|
|
|
KPS AG: Aufsichtsrat bestellt Michael Hessing als neuen Finanzvorstand, Vertrag von Vorstandsmitglied Leonardo Musso verlängert...
|
|
|
13.02.26 - 13:33
|
Ad-hoc News: KPS AG (EQS)
|
|
|
KPS AG: Erweiterung des Vorstands um neuen CFO und vorzeitige Wiederbestellung des Vorstands Leonardo Musso...
|
|
|
|
|
|
|
|
|
|
|
|
|
02.02.26 - 14:09
|
In Spaceflight Conditions: N2OFF′s MitoCareX Bio Highlights Co-Founder′s Innovative Research on Mitochondrial Carriers in Microgravity and Cosmic radiation Conditions (GlobeNewswire EN)
|
|
|
Neve Yarak, Israel, Feb. 02, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), a specialty biotechnology company developing small‑molecule drugs that target human mitochondrial carriers, its wholly- owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation....
|
|
|
02.02.26 - 13:03
|
Alterome Therapeutics Appoints Leo Faoro, MD, MBA, as Chief Medical Officer (Business Wire)
|
|
|
Veteran medical oncologist with a proven track record of advancing cancer therapies from early trials through regulatory approval to lead ongoing clinical development of ALTA2618 and ALTA3263SAN DIEGO--(BUSINESS WIRE)--Alterome Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the development of next-generation, small molecule targeted therapies for the treatment of cancer, today announced the appointment of Leonardo Faoro, MD, MBA, as Chief Medical Officer (CMO). Most recently, Dr. Faoro was CMO at Quanta Therapeutics, where he oversaw the clinical development of several novel KRAS inhibitors. Dr. Faoro will lead the ongoing clinical development of ALTA3263, a pan-KRAS ON/OFF inhibitor, and ALTA2618, a mutation-selective inhibitor for AKT1-driven cancers, both currently in Phase 1/1b development with initial data expected in 2026.
“Alterome has made great progress in treating the most aggressive and difficult to treat cancers with two potential best-in-class programs that we adv...
|
|
|
|
|
|
|
|
|
|
|
|
|
26.01.26 - 12:00
|
Leonardo-Aktie: Die italienische Rheinmetall? (Sharedeals)
|
|
|
Die Leonardo-Aktie ist wie alle Rüstungsaktien ein Profiteur des Ukrainekriegs. Seit Oktober 2022 befindet sie sich in einem langfristigen Aufwärtstrend. In der Spitze lag der Kursgewinn bei rund +650%. Am Montag verliert sie aktuell -1,6% und steht bei 57,20 €. Wie sind die weiteren Aussichten? Intensivierung der Kooperation zwischen Deutschland und Italien Bei einem Treffen […]
The post Leonardo-Aktie: Die italienische Rheinmetall? first appeared on sharedeals.de....
|
|
|
20.01.26 - 16:18
|
UK Defense Funding Delay Threatens Key Leonardo Site, Union Says (Bloomberg)
|
|
|
Leonardo SpA's British helicopter factory will close if UK funding delays prevent a contract with the Italian manufacturer before March, union leaders said in a letter to Prime Minister Keir Starmer, showing how the government's failure to commit cash is throwing plans for a revamped defense sector in doubt....
|
|
|
|
|
15.01.26 - 14:36
|
N2OFF: MitoCareX Bio Spotlights Co-Founder′s Pioneering Research on Mitochondrial Carriers in Spaceflight Stress Conditions (GlobeNewswire EN)
|
|
|
Neve Yarak, Israel, Jan. 15, 2026 (GLOBE NEWSWIRE) -- N2OFF, Inc. (NASDAQ: NITO) (“N2OFF” and the “Company”), a drug discovery company that is also investing in solar energy assets based on the RTB (Ready to Build) business model, today highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio Ltd. (“MitoCareX Bio”), N2OFF's wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation....
|
|
|
15.01.26 - 13:36
|
Renovus Capital Partners Announces Team Promotions (Business Wire)
|
|
|
WAYNE, Pa.--(BUSINESS WIRE)--Renovus Capital Partners (“Renovus”), a Philadelphia-area based investment firm, announced today the promotions of several team members:
Pat Heath to Principal from Vice President
John Matthews to Vice President from Senior Associate
Adam Swack to Vice President from Senior Associate
Ried Niermann to Senior Associate from Associate
Ahan Patel to Senior Associate from Associate
Fernando Cordova to Associate from Analyst
Luca Di Leonardo to Associate from Analyst
Jackson Kelly to Associate from Analyst
Kevin Spear to Associate from Analyst
Jisa Ben to Fund Accounting Manager from Senior Fund Accountant
Matthew Stretch to Senior Fund Accountant from Fund Accountant
“We are pleased to recognize these talented professionals with well-deserved promotions,” said Jesse Serventi, Founding Partner at Renovus. “Each of these individuals has played an important role in advancing the firm's growth through consistent performance, collaboration, and leadership. Together with my fe...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
